Today: 12 May 2026
British American Tobacco share price: BAT set for spotlight after AI job-cut warning and 2026 buyback plan
13 February 2026
2 mins read

British American Tobacco share price: BAT set for spotlight after AI job-cut warning and 2026 buyback plan

London, Feb 13, 2026, 07:58 GMT — Premarket

  • BAT slipped 0.5% to finish at 4,404p on Thursday, just before London’s Friday open
  • After reporting full-year numbers, the company signaled it may cut jobs as part of a drive to boost productivity using AI.
  • Attention shifts to cost-cutting moves, how the buyback plays out, and what the U.S. plans to do about illegal disposable vapes.

Shares of British American Tobacco p.l.c. (BATS.L) slipped 0.5% to close at 4,404 pence on Thursday, after moving in a range from 4,278 to 4,484 pence. The company flagged to investors that its push for productivity through AI might lead to job reductions, keeping attention on the stock before Friday’s session.

Here’s why it’s worth paying attention: BAT is under pressure to deliver fatter profits from traditional cigarettes, even as it nudges customers over to newer nicotine options. Shareholders want their payouts, sure, but they’re also watching for any stumbles as the company pivots.

Tension has only grown after the stock’s solid performance this past year. Sceptics remain when it comes to “modern oral” and vaping—those doubts haven’t faded. And, once again, the U.S. illicit trade story isn’t going away.

Interim CFO Javed Iqbal acknowledged the productivity push “will have an impact on the size of the organisation,” but declined to specify how many jobs might be affected. The company remains in the consultation process. Reuters

BAT posted full-year revenue of 25.61 billion pounds for 2025, slipping 1.0% on a reported basis but climbing 2.1% at constant exchange rates — that metric smooths out currency effects. Adjusted operating profit rose 2.3% to 11.279 billion pounds, with adjusted diluted EPS up 3.4% to 340.5 pence, according to the report.

BAT reaffirmed its mid-term growth targets for 2026, steering guidance toward the lower end. The company bumped its dividend up by 2.0%, setting it at 245.04 pence per share, and rolled out plans for a £1.3 billion buyback in 2026. “I am pleased with our accelerating momentum through 2025,” CEO Tadeu Marroco said in the results statement. BAT

Broker opinions split. Jefferies’ Andrei Andon-Ionita stuck with a buy call and left his 5,200 pence target unchanged, a note seen on MarketScreener showed.

RBC stuck to its sell rating, holding the target at 3,600 pence. JP Morgan, on the other hand, stayed neutral with a 4,150 pence target, according to MarketScreener’s note summaries.

Investors across the industry are keeping an eye on how aggressively U.S. regulators target disposable vapes. BAT flagged that a possible U.S. import ban on unauthorized products might slash the unregulated market by as much as a third. The company figures about 70% of U.S. e-cigarette sales come from unregulated devices. Still, Marroco played down the risk, saying any blow likely wouldn’t count as a “material impact” until supply-chain inventories run down. Reuters

BAT reported picking up 129,826 shares on Feb. 11, paying between 4,390 and 4,450 pence apiece, with plans to cancel the lot. The buybacks have helped prop up the stock—especially as investors continue to look for solid proof that BAT’s newer categories can deliver growth without relying on steep discounts.

But plenty could still sour here. Dragged-out consultations on job cuts, or a tougher-than-expected crackdown on the illicit vape market, could rattle sentiment fast — especially with 2026 growth already pegged at the low end.

On Friday, all eyes turn to BAT as London trading resumes, with investors keen for more specifics on job cuts and the buyback schedule. Attention is also fixed on the looming U.S. International Trade Commission ruling, due in March, followed by a 60-day presidential review—a sequence BAT calls out as the next major milestone.

Stock Market Today

  • QuantumScape Shares Rise 9.35% After Q1 Earnings Beat Expectations
    May 12, 2026, 5:51 PM EDT. QuantumScape Corporation (NASDAQ: QS) shares jumped 9.35% following its Q1 2026 earnings report, which showed a smaller-than-expected loss of $0.16 per share versus Wall Street's forecast of $0.18. Despite continuing losses of $100.8 million driven by heavy R&D spending, QS's strong cash position of $904.7 million and a working capital cushion of $872.1 million reassure investors. The stock's advance from mid-$6s in late April to around $8.26 on May 11 reflects growing optimism about the firm's solid-state lithium-metal battery technology. Market participants remain focused on progress toward commercialization, with robust trading momentum indicating confidence in QS's potential for electric vehicle applications.

Latest article

British American Tobacco Stock Jumps as FDA Shift Gives Vuse and Velo a Cleaner Read

British American Tobacco Stock Jumps as FDA Shift Gives Vuse and Velo a Cleaner Read

12 May 2026
British American Tobacco shares jumped 5.82% in London to £46.34 after the FDA signaled a softer enforcement stance on some e-cigarette and nicotine pouch products. A U.S. judge also dismissed BAT’s North Korea sanctions case following a $630 million settlement. The FTSE 100 slipped 0.04%. BAT’s U.S.-listed ADR closed up 5.3% at $63.64.
Camtek Stock Falls 16% After Earnings Beat as Margin Pressure and Hot CPI Hit AI Chip Trade

Camtek Stock Falls 16% After Earnings Beat as Margin Pressure and Hot CPI Hit AI Chip Trade

12 May 2026
Camtek shares fell 15.8% to $174.63 despite beating Q1 revenue and adjusted EPS estimates by small margins. Q1 revenue rose 2.5% year over year, but non-GAAP EPS dropped to $0.70 from $0.79 and operating margin narrowed to 25.5%. Management guided Q2 revenue to $129–$131 million and expects second-half revenue to rise over 25%. Broader market pressure followed a hot April CPI and rising Treasury yields.
Oscar Health stock rises in premarket after 2026 revenue outlook; House subpoenas add a fresh risk

Oscar Health Stock Extends Post-Earnings Repricing as Margins Outweigh ACA Risk

12 May 2026
Oscar Health shares rose 7.9% to $23.73 late Tuesday, with volume near 13 million, after posting strong Q1 profit and lower claims costs despite missing revenue estimates. The company’s medical loss ratio fell to 70.5% from 75.4% a year earlier. Membership climbed to 3.17 million. ACA enrollment churn and policy risk remain concerns.
RELX share price today: £450m buyback and AI talk in focus before London open
Previous Story

RELX share price today: £450m buyback and AI talk in focus before London open

Lloyds share price slips in London as buyback rolls on and UK rate-cut bets loom
Next Story

Lloyds share price slips in London as buyback rolls on and UK rate-cut bets loom

Go toTop